Canada Pension Plan Investment Board Purchases Shares of 22,360 Mural Oncology plc (NASDAQ:MURA)

Canada Pension Plan Investment Board acquired a new position in shares of Mural Oncology plc (NASDAQ:MURA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 22,360 shares of the company’s stock, valued at approximately $70,000. Canada Pension Plan Investment Board owned approximately 0.13% of Mural Oncology at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in Mural Oncology during the 2nd quarter valued at $998,000. Primecap Management Co. CA acquired a new stake in shares of Mural Oncology in the second quarter valued at $740,000. Renaissance Technologies LLC bought a new position in shares of Mural Oncology in the second quarter valued at about $729,000. Nicollet Investment Management Inc. acquired a new position in Mural Oncology during the 2nd quarter worth about $308,000. Finally, Harbor Capital Advisors Inc. bought a new stake in Mural Oncology during the 2nd quarter worth about $115,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Price Performance

NASDAQ MURA opened at $3.05 on Monday. Mural Oncology plc has a 52 week low of $2.88 and a 52 week high of $17.00. The stock has a fifty day moving average of $3.28 and a 200-day moving average of $3.57.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $0.04. On average, sell-side analysts anticipate that Mural Oncology plc will post -7.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mural Oncology news, CEO Caroline Loew sold 12,531 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $2.91, for a total value of $36,465.21. Following the transaction, the chief executive officer now directly owns 240,391 shares of the company’s stock, valued at $699,537.81. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Rodman & Renshaw initiated coverage on shares of Mural Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $15.00 target price for the company.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.